Complementary Effects of Multivitamin and Omega-3 Fatty Acid Supplementation on Indices of Cardiovascular Health in Individuals with Elevated Homocysteine
Complementary Effects of Multivitamin and Omega-3 Fatty Acid Supplementation on Indices of Cardiovascular Health in Individuals with Elevated Homocysteine
复制标题
DOI：
10.1024/0300-9831/a000093
复制
发表时间：
2012-02-01
影响因子：
2.3
通讯作者：
Church, Timothy S.
中科院分区：
文献类型：
--
作者：
Earnest, Conrad P.;Kupper, Jennifer S.;Church, Timothy S.
同型半胱氨酸（HCY）、c反应蛋白（hsCRP）和甘油三酯（TG）是心血管疾病（CVD）的危险因素。虽然多种维生素（MVit）可以降低HCY和hsCRP，但omega-3脂肪酸（N3）可以降低TG；然而，他们很少同时学习。我们随机分配了100名基线HCY （> 8.0 μ mol/L）的参与者，每天摄入：(1)安慰剂，(2)MVit（维生素c: 200毫克；维生素e: 400 IU； VitB6: 25毫克；叶酸：400微克；维生素b12: 400微克）+安慰剂，(3)N3(2克N3, 760毫克EPA， 440毫克DHA) +安慰剂，或(4)MVit + N3，持续12周。在随访中，我们观察到MVit组（-1.43,95% CI, -2.39, -0.47）和MVit + N3组（-1.01,95% CI, -1.98, -0.04）的HCY （umol/L）显著降低，与安慰剂组（-0.57,95% CI, -1.49,0.35）和N3组（1.11,95% CI, 0.07, 2.17）相比均显著（p < 0.05）。hsCRP （nmol/L）在MVit组（-6.00,95% CI, -1.04, -0.15）和MVit + N3组（-0.98,95% CI, -1.51, -0.46）显著降低，但与安慰剂组（-0.15,95% CI, -0.74,0.43）或N3组（-0.53,95% CI, -1.18, 0.12）相比无显著降低。最后，我们观察到N3组（-0.41,95% CI, -0.69, -0.13）和MVit + N3组（-0.71,95% CI, -0.93, -0.46） TG显著降低，与安慰剂组（-0.10,95% CI, -0.36, 0.17）和MVit组（0.15,95% CI, -12, 0.42）相比均显著降低。MVit + N3的共同摄入对HCY、hsCRP和血浆TG具有协同作用。
Homocysteine (HCY), C-reactive protein (hsCRP), and triglycerides (TG) are risk factors for cardiovascular disease (CVD). While multivitamins (MVit) may reduce HCY and hsCRP, omega-3 fatty acids (N3) reduce TG; yet, they are seldom studied simultaneously. We randomly assigned 100 participants with baseline HCY (> 8.0 umol/L) to the daily ingestion of: (1) placebo, (2) MVit (VitC: 200 mg; VitE: 400 IU; VitB6: 25 mg; Folic Acid: 400 ug; VitB12: 400 ug) + placebo, (3) N3 (2 g N3, 760 mg EPA, 440 mg DHA) + placebo, or (4) MVit + N3 for 12 weeks. At follow-up, we observed significant reductions in HCY (umol/L) for the MVit (-1.43, 95 %CI, -2.39, -0.47) and MVit + N3 groups (-1.01, 95 %CI, -1.98, -0.04) groups, both being significant (p < 0.05) vs. placebo (-0.57, 95 %CI, -1.49,0.35) and N3 (1.11, 95 % CI, 0.07, 2.17). hsCRP (nmol/L) was significantly reduced in the MVit (-6.00, 95 %CI, -1.04, -0.15) and MVit + N3 (-0.98, 95 %CI, -1.51, -0.46) groups, but not vs. placebo (-0.15, 95 %CI, -0.74,0.43) or N3 (-0.53,95 %CI, -1.18, 0.12). Lastly, we observed significant reductions in TG for the N3 (-0.41, 95 %CI, -0.69, -0.13) and MVit + N3 (-0.71, 95 %CI, -0.93, -0.46) groups, both significant vs. placebo (-0.10, 95 %CI, -0.36, 0.17) and MVit groups (0.15, 95 %CI, -12, 0.42). The co-ingestion of MVit + N3 provides synergistic affects on HCY, hsCRP, and plasma TG.